Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?
Saved in:
| Main Authors: | Nancy E. Lane, Lee S. Simon, Jeyanesh Tambiah |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Osteoarthritis and Cartilage Open |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2665913124001134 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of the therapeutic benefits of symptomatic slow acting drugs in osteoarthritis: emphasis on structural-modifying action
by: I. B. Belyaeva, et al.
Published: (2021-12-01) -
Chronic back pain as a spinal osteoarthritis manifestation: rationale and practice of symptomatic slow acting drugs for osteoarthritis use
by: A. E. Karateev
Published: (2022-08-01) -
Advantages of osteoarthritis combined treatment with symptomatic slow-acting drugs
by: E. V. Zonova
Published: (2021-04-01) -
Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs
by: N. V. Chichasova, et al.
Published: (2015-06-01) -
Effect of Deep Slow Breathing on Pain-Related Variables in Osteoarthritis
by: Kalee L. Larsen, et al.
Published: (2019-01-01)